All > Sbrt > Liver Cancer

TACE Plus Stereotactic Body Radiation Therapy (SBRT) for Liver Cancer

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
London Health Sciences Centre, London Regional Cancer Program, London, CanadaLiver CancerTransarterial Chemoembolization - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether adding a specialized radiation treatment to the standard chemotherapy treatment for liver cancer will help control the cancer better.

Eligible Conditions
  • Liver Cancer

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Similar Trials

1
Stereotactic Body Radiation Therapy
1
Radiation Therapy
1
Stereotactic Body Radiation Therapy (SBRT)

Study Objectives

2 Primary · 13 Secondary · Reporting Duration: 5 years

5 years
Local Failure
Year 2
Overall Survival
Patients will be assessed at least once during radiation therapy for toxicity
Radiation Therapy Toxicity Assessment
Month 3
Change in Health related Quality of Life (QOL)
Year 2
Liver Related Quality of Life (QOL)
Overall Quality of Life (QOL)
Quality of Life (QOL)
Year 2
Extrahepatic failure
Time to Intrahepatic Progression
Time to intrahepatic progression
The sum of the longest diameter (LD) for all target lesions will be calculated and reported as the baseline sum LD. The baseline sum LD will be used as reference by which to characterize the objective tumor.
Measurement of Response Rate
Year 2
Cost-benefit
Year 2
Radiation Therapy Classic Radiation Toxicity Assessment
Year 2
Radiation Therapy Non-Classic Toxicity Assessment
Therapeutic radiology procedure

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
Stereotactic Body Radiation Therapy
1
Radiation Therapy
2
Stereotactic Body Radiation Therapy (SBRT)

Trial Design

2 Treatment Groups

TACE Plus Stereotactic Body Radiation Therapy (SBRT)
1 of 2
Transarterial Chemoembolization (TACE)
1 of 2

Active Control

128 Total Participants · 2 Treatment Groups

Primary Treatment: TACE Plus Stereotactic Body Radiation Therapy (SBRT) · No Placebo Group · Phase 3

TACE Plus Stereotactic Body Radiation Therapy (SBRT)
Radiation
ActiveComparator Group · 1 Intervention: Stereotactic Body Radiation · Intervention Types: Radiation
Transarterial Chemoembolization (TACE)
Drug
ActiveComparator Group · 1 Intervention: Transarterial Chemoembolization · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
620 Previous Clinical Trials
403,126 Total Patients Enrolled
Michael Lock, M.D.Principal InvestigatorLawson Health Research Institute

Eligibility Criteria

Age 18+ · All Participants · 26 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You may have cancer in other parts of your body, but if the cancer has spread to your liver and is life-threatening, you may still participate in the study.
Your condition cannot be treated with surgery.
If you have cancer in your liver, it can be treated with TACE.
You are expected to live for at least 6 more months.
If you had surgery or therapy to remove liver tissue before, you can still participate in the study.
References

Frequently Asked Questions

What are doctors and researchers hoping to study and discover through this clinical trial?

"The success of this clinical trial will be judged by the patients' Overall Survival rates, which will be measured before treatment, 1 month, 3 months, and then every 3 months up to 2 years. Additionally, the Radiation Therapy Classic Radiation Toxicity Assessment (defined as Classic RILD), the Response Rate (defined as Modified RECIST), and the Radiation Therapy Overall Toxicity Assessment (defined as CTC V4.0) will be secondary measures of success." - Anonymous Online Contributor

Unverified Answer

How many individuals are partaking in this clinical trial?

"The trial is ongoing and is currently looking for 128 patients at a single site, according to the listing on clinicaltrials.gov. This particular study was first posted on 5/27/2019, with the most recent update on 11/10/2021." - Anonymous Online Contributor

Unverified Answer

Does the FDA recognize TACE Plus Stereotactic Body Radiation Therapy (SBRT) as an effective treatment?

"TACE Plus Stereotactic Body Radiation Therapy (SBRT) is estimated to be a 3 on a scale of 1 to 3 in terms of safety." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top